A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

This study is testing a new CAR-T cell therapy called A-CAR028 for people with relapsed or treatment-resistant acute myeloid leukemia (AML) — a fast-growing blood cancer. CAR-T therapy involves engineering a patient's own immune cells to attack the cancer. **You may be eligible if...** - You are 18–75 years old - You have AML that has come back or stopped responding to treatment - Your ECOG performance status is 0 or 1 (able to carry out normal activities) - Your major organ functions are within acceptable range - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - You have a specific subtype called acute promyelocytic leukemia (APL) or mixed phenotype acute leukemia - You have only disease outside the bone marrow (extramedullary only) - You have had a stem cell transplant within the past 3 months - You have had a heart attack, serious heart disease, or a pacemaker in the past year Talk to your doctor to see if this trial is right for you.